ClinicalTrials.gg
CompletedNCT02293395GEMINI ACS 1Updated Dec 26, 2017Results posted

A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome

A Phase 2 interventional study of Acetylsalicylic acid and Rivaroxaban in Acute Coronary Syndrome, sponsored by Janssen Research & Development, LLC. Completed at 262 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-12-26.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
3,037
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing rivaroxaban in Acute Coronary Syndrome — 2 open to participants now, 2 under way, none of them phase 3. Rivaroxaban · Acute Coronary Syndrome.

Enrollment
4th of 13
3,037 · median 261
Started
2015
the only one that year
Phase 2
3 of 13
none open now
Registered
4th of 13
by date
Lead sponsor
1 of 13
Janssen Research & Development, LLC

Among the 13 studies testing rivaroxaban in Acute Coronary Syndrome, this one is the 4th largest by enrollment, is the only one that started in 2015, is one of 3 in phase 2, and was the 4th registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 273 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

2 of the 13 studies testing rivaroxaban in Acute Coronary Syndrome are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About rivaroxaban

Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 196 Acute Coronary Syndrome studies recruiting now, 145 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing rivaroxaban in Acute Coronary Syndrome, or all of them as a file.
02

Study summary

The purpose of this study is to estimate the risk of bleeding with rivaroxaban, compared with acetylsalicylic acid (ASA), in addition to a single antiplatelet/ platelet adenosine diphosphate P2Y12 receptor antagonist (P2Y12 inhibitor agent: clopidogrel or ticagrelor), in participants with a recent acute coronary syndrome (ACS: including ST segment elevation myocardial infarction [STEMI] and non-ST-segment elevation acute coronary syndrome [NSTE-ACS]).

Read the detailed description

This is a prospective, randomized (the study drug is assigned by chance), double-blind (neither physician nor participant knows the treatment that the participant receives), active-controlled (study in which the experimental treatment or procedure is compared to a standard treatment or procedure), parallel group (each group of participants will be treated at the same time), multicenter (when more than one hospital or medical school team work on a medical research study) study in participants with a recent ACS (STEMI or NSTE-ACS). All the eligible participants receiving background treatment of ASA plus clopidogrel (Stratum 1) or ASA plus ticagrelor (Stratum 2) will be randomly assigned to either receive ASA or rivaroxaban on background of P2Y12 receptor antagonists treatment. This study will include 3 phases: Screening Phase (up to 10 days, before study start on Day 1), Double-blind Treatment Phase (up to either 180 days after randomization of the last enrolled participant in the study or Day 360, whichever occurs earlier), and Follow-up Phase (up to 30 days). Participants' safety will be monitored throughout the study.

03

Conditions studied

  • Acute Coronary Syndrome

Keywords

  • Acute Coronary Syndrome
  • Myocardial infarction
  • Unstable angina
  • Acetylsalicylic acid
  • Rivaroxaban
  • JNJ-39039039
  • Bay 59-7939
  • Xarelto
  • Clopidogrel
  • Ticagrelor
  • Plavix
  • Brilinta
  • Effient
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants, 18 years or older, must have symptoms suggestive of acute coronary syndrome (ACS) (angina, or symptoms thought to be equivalent) within 48 hours of hospital presentation, or developed ACS while being hospitalized, and has a diagnosis of: a) ST segment elevation myocardial infarction (STEMI); b) non-ST-segment elevation acute coronary syndrome (NSTE-ACS). However, participant who is 54 years of age or younger must also have either diabetes mellitus or a history of a prior myocardial infarction (MI), in addition to the presenting ACS event
  • Participant must be randomized within the screening window of 10 days after hospital admission for the index ACS event. Participant should have received acute phase treatment for the index ACS, such as intravenous anticoagulant or antiplatelet, and are receiving maintenance dual antiplatelet therapy (DAPT) with either clopidogrel plus acetyl salicylic acid (ASA), or ticagrelor plus ASA, with the intent to continue the treatment with a adenosine diphosphate P2Y12 receptor antagonist (P2Y12 inhibitor) after randomization
  • Participants must agree to provide a pharmacogenomics deoxyribonucleic acid (DNA) sample

Exclusion criteria

Exclusion Criteria:

  • Participant has any conditions that, in the opinion of the investigator, contraindicates anticoagulant therapy or would have an unacceptable risk
  • Participant with a prior stroke of any etiology or (TIA)
  • Participant who received thrombolytic therapy as treatment for the index ACS event cannot be enrolled in the ticagrelor stratum
  • Participant has anticipated need for chronic administration of omeprazole or esomeprazole concomitantly with clopidogrel
  • Participant has known allergy or intolerance to ASA or rivaroxaban
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
3,037 participants (actual)

Study arms

  • Active comparator
    Stratum 1/ASA

    Acetylsalicylic acid (ASA) 100 milligram (mg) enteric-coated tablet once daily orally along with clopidogrel 75 mg once daily orally, up to either 180 days after randomization of the last enrolled participant in the study or Day 360, whichever occurs earlier.

    Drug: Acetylsalicylic acid · Drug: Clopidogrel

  • Experimental
    Stratum 1/Rivaroxaban

    Rivaroxaban 2.5 mg tablet twice daily orally along with clopidogrel 75 mg once daily orally, up to either 180 days after randomization of the last enrolled participant in the study or Day 360, whichever occurs earlier.

    Drug: Rivaroxaban · Drug: Clopidogrel

  • Active comparator
    Stratum 2/ASA

    ASA 100 mg enteric-coated tablet once daily orally along with ticagrelor 90 mg twice daily orally, up to either 180 days after randomization of the last enrolled participant in the study or Day 360, whichever occurs earlier.

    Drug: Acetylsalicylic acid · Drug: Ticagrelor

  • Experimental
    Stratum 2/Rivaroxaban

    Rivaroxaban 2.5 mg tablet twice daily orally along with ticagrelor 90 mg twice daily orally, up to either 180 days after randomization of the last enrolled participant in the study or Day 360, whichever occurs earlier.

    Drug: Rivaroxaban · Drug: Ticagrelor

Interventions

  • ASA 100 mg enteric-coated tablet once daily orally.

    Also known as: Aspirin

  • Rivaroxaban 2.5 mg tablet twice daily orally.

    Also known as: JNJ-39039039, Bay 59-7939, Xarelto

  • Clopidogrel 75 mg once daily orally.

    Also known as: Plavix

  • Ticagrelor 90 mg twice daily orally.

    Also known as: Brilinta

06

What researchers measure

Primary outcomes

  1. Number of Participants With Non Coronary Artery Bypass Graft-Related (Non CABG-related) Thrombolysis in Myocardial Infarction (TIMI) Clinically Significant Bleeding Events

    Non CABG-related TIMI clinically significant bleeding events are sum of non CABG-related TIMI major bleeding events, TIMI minor bleeding events and TIMI bleeding events requiring medical attention. Major: any symptomatic intracranial bleeding: clinically overt signs of hemorrhage with hemoglobin (Hb) drop of greater than or equal to (\>=)5 gram per deciliter (g/dl) (or absolute drop in hematocrit of \>=15%) and fatal bleeding (results in death within 7 days); Minor: clinically overt sign of hemorrhage with Hb drop of 3 - \<5 g/dl (or drop in hematocrit of 9 - \<15%); requiring medical attention: bleeding event that required medical, surgical treatment/laboratory evaluation and did not meet criteria for major/minor bleeding event.

    Time frame: From start of study treatment until follow-up (up to 390 days)

07

Results

Posted Nov 13, 2017
Limitations and caveats
Study population was homogenous with limited participation of non-Caucasian participants. Randomization was not performed for use of P2Y12 inhibitor; strata comparisons between bleeding and efficacy endpoints are confounded and were not planned.

Participant flow

Participant flow — Overall Study
MilestoneRivaroxaban 2.5 mg Twice Daily (BID)Acetylsalicylic Acid 100 mg Once Daily (OD)
Started15191518
Treated15101506
Completed15101511
Not completed97
Withdrew: Lost to follow-up10
Withdrew: Withdrawal by subject87

Outcome measures

PrimaryNumber of Participants With Non Coronary Artery Bypass Graft-Related (Non CABG-related) Thrombolysis in Myocardial Infarction (TIMI) Clinically Significant Bleeding Events

Non CABG-related TIMI clinically significant bleeding events are sum of non CABG-related TIMI major bleeding events, TIMI minor bleeding events and TIMI bleeding events requiring medical attention. Major: any symptomatic intracranial bleeding: clinically overt signs of hemorrhage with hemoglobin (Hb) drop of greater than or equal to (\>=)5 gram per deciliter (g/dl) (or absolute drop in hematocrit of \>=15%) and fatal bleeding (results in death within 7 days); Minor: clinically overt sign of hemorrhage with Hb drop of 3 - \<5 g/dl (or drop in hematocrit of 9 - \<15%); requiring medical attention: bleeding event that required medical, surgical treatment/laboratory evaluation and did not meet criteria for major/minor bleeding event.

Time frame:
From start of study treatment until follow-up (up to 390 days)
Reported as:
Number · participants
Number of Participants With Non Coronary Artery Bypass Graft-Related (Non CABG-related) Thrombolysis in Myocardial Infarction (TIMI) Clinically Significant Bleeding Events
participantsRivaroxaban 2.5 mg Twice Daily (BID)Acetylsalicylic Acid 100 mg Once Daily (OD)
Number of Participants With Non Coronary Artery Bypass Graft-Related (Non CABG-related) Thrombolysis in Myocardial Infarction (TIMI) Clinically Significant Bleeding Events8074
Statistical analysis
  • Rivaroxaban 2.5 mg Twice Daily (BID) vs Acetylsalicylic Acid 100 mg Once Daily (OD) · Log Rank · p = 0.584 · Hazard ratio (hr): 1.09 · 95% CI 0.8 to 1.5

Adverse events

Collected over Up to 390 days. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rivaroxaban 2.5 mg Twice Daily (BID)—125/1,510 (8.3%)81/1,510 (5.4%)
Acetylsalicylic Acid 100 mg Once Daily (OD)—138/1,506 (9.2%)84/1,506 (5.6%)
Most frequent serious events
Showing 10 of 172
Most frequent serious events
EventRivaroxaban 2.5 mg Twice Daily (BID)Acetylsalicylic Acid 100 mg Once Daily (OD)
Cardiac FailureCardiac disorders9/15107/1506
Atrial FibrillationCardiac disorders3/15107/1506
PneumoniaInfections and infestations7/15105/1506
Angina UnstableCardiac disorders5/15105/1506
Cholecystitis AcuteHepatobiliary disorders3/15105/1506
Hypertensive CrisisVascular disorders5/15102/1506
DyspnoeaRespiratory, thoracic and mediastinal disorders4/15104/1506
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders0/15104/1506
Coronary Artery RestenosisInjury, poisoning and procedural complications1/15103/1506
SyncopeNervous system disorders2/15103/1506
Most frequent other events
Most frequent other events
EventRivaroxaban 2.5 mg Twice Daily (BID)Acetylsalicylic Acid 100 mg Once Daily (OD)
DyspnoeaRespiratory, thoracic and mediastinal disorders33/151039/1506
HypertensionVascular disorders23/151022/1506
Chest PainGeneral disorders11/151019/1506
CoughRespiratory, thoracic and mediastinal disorders16/151014/1506

Baseline characteristics

Age, Continuous
Age, Continuous(years)Rivaroxaban 2.5 mg Twice Daily (BID)Acetylsalicylic Acid 100 mg Once Daily (OD)Total
Mean62.7 ± 9.1462.9 ± 8.8262.8 ± 8.98
Sex: Female, Male
Sex: Female, Male(Participants)Rivaroxaban 2.5 mg Twice Daily (BID)Acetylsalicylic Acid 100 mg Once Daily (OD)Total
Female385377762
Male113411412275
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Rivaroxaban 2.5 mg Twice Daily (BID)Acetylsalicylic Acid 100 mg Once Daily (OD)Total
White141714072824
Black241640
Asian5463117
Others243256
Region of Enrollment
Region of Enrollment(participants)Rivaroxaban 2.5 mg Twice Daily (BID)Acetylsalicylic Acid 100 mg Once Daily (OD)Total
ARGENTINA6665131
AUSTRALIA181735
BELGIUM494089
BRAZIL7785162
BULGARIA8378161
CANADA374784
CZECH REPUBLIC343771
DENMARK123
FRANCE282957
HUNGARY101100201
ITALY7559134
JAPAN263359
NETHERLANDS6965134
POLAND158175333
RUSSIA237244481
SPAIN6260122
SWEDEN423779
TURKEY10298200
UKRAINE137129266
UNITED STATES9388181
Korea, Republic Of243054
08

Study locations

262 sites
  • Alexander City, Alabama, United States
  • Banning, California, United States
  • Sylmar, California, United States
  • Aurora, Colorado, United States
  • Littleton, Colorado, United States
  • Jupiter, Florida, United States
  • Miami, Florida, United States
  • Orlando, Florida, United States
  • Pensacola, Florida, United States
  • Tampa, Florida, United States
  • Athens, Georgia, United States
  • Cumming, Georgia, United States
  • Macon, Georgia, United States
  • Tucker, Georgia, United States
  • Boise, Idaho, United States
  • Coeur d'Alene, Idaho, United States
  • Jerseyville, Illinois, United States
  • Indianapolis, Indiana, United States
  • Munster, Indiana, United States
  • Bay City, Michigan, United States
  • Kalamazoo, Michigan, United States
  • Lansing, Michigan, United States
  • Mount Clemens, Michigan, United States
  • Ypsilanti, Michigan, United States
  • Minneapolis, Minnesota, United States
  • Columbia, Missouri, United States
  • Saint Louis, Missouri, United States
  • Kalispell, Montana, United States
  • Stony Brook, New York, United States
  • Rocky Mount, North Carolina, United States
  • Sanford, North Carolina, United States
  • Cincinnati, Ohio, United States
  • Zanesville, Ohio, United States
  • Bartlesville, Oklahoma, United States
  • Tulsa, Oklahoma, United States
  • Abington, Pennsylvania, United States
  • Langhorne, Pennsylvania, United States
  • Philadelphia, Pennsylvania, United States
  • Sayre, Pennsylvania, United States
  • York, Pennsylvania, United States
  • Rapid City, South Dakota, United States
  • Oak Ridge, Tennessee, United States
  • Amarillo, Texas, United States
  • Fort Sam Houston, Texas, United States
  • Houston, Texas, United States
  • Odessa, Texas, United States
  • San Antonio, Texas, United States
  • Danville, Virginia, United States
  • Puyallup, Washington, United States
  • Buenos Aires, Argentina
  • Caba, Argentina
  • Ciudad De Buenos Aires, Argentina
  • Cordooba, Argentina
  • Corrientes, Argentina
  • Córdoba, Argentina
  • La Plata, Argentina
  • Mar Del Plata, Argentina
  • Resistencia, Argentina
  • Rosario, Argentina
  • Salta, Argentina
  • San Martín, Argentina
  • Santa Fe, Argentina
  • Brisbane, Australia
  • Cairns, Australia
  • Chermside, Australia
  • Elizabeth Vale, Australia
  • Herston, Australia
  • Hobart, Australia
  • Launceston, Australia
  • Liverpool, Australia
  • Murdoch, Australia
  • Nambour, Australia
  • New Lambton Heights, Australia
  • Antwerpen, Belgium
  • Bonheiden, Belgium
  • Brasschaat, Belgium
  • Brugge, Belgium
  • Edegem, Belgium
  • Genk, Belgium
  • Gent, Belgium
  • Huy, Belgium
  • Liège, Belgium
  • Mol, Belgium
  • Roeselare, Belgium
  • Ronse, Belgium
  • Turnhout, Belgium
  • Belo Horizonte, Brazil
  • Blumenau, Brazil
  • Campina Grande Do Sul, Brazil
  • Campinas, Brazil
  • Curitiba, Brazil
  • Marília, Brazil
  • Passo Fundo, Brazil
  • Porto Alegre, Brazil
  • Recife, Brazil
  • Salvador, Brazil
  • São José Do Rio Preto, Brazil
  • São Paulo, Brazil
  • Tatuí, Brazil
  • Uberlândia, Brazil

Showing the first 100 of 262 sites across 20 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Gibson WJ, Nafee T, Travis R, Yee M, Kerneis M, Ohman M, Gibson CM. Machine learning versus traditional risk stratification methods in acute coronary syndrome: a pooled randomized clinical trial analysis. J Thromb Thrombolysis. 2020 Jan;49(1):1-9. doi: 10.1007/s11239-019-01940-8. PubMed 31535314 ↗
  • Povsic TJ, Ohman EM, Roe MT, White J, Rockhold FW, Montalescot G, Cornel JH, Nicolau JC, Steg PG, James S, Bode C, Welsh RC, Plotnikov AN, Mundl H, Gibson CM. P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes. JAMA Cardiol. 2019 Jul 1;4(7):680-684. doi: 10.1001/jamacardio.2019.1510. PubMed 31141104 ↗
  • Ohman EM, Roe MT, Steg PG, James SK, Povsic TJ, White J, Rockhold F, Plotnikov A, Mundl H, Strony J, Sun X, Husted S, Tendera M, Montalescot G, Bahit MC, Ardissino D, Bueno H, Claeys MJ, Nicolau JC, Cornel JH, Goto S, Kiss RG, Guray U, Park DW, Bode C, Welsh RC, Gibson CM. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. Lancet. 2017 May 6;389(10081):1799-1808. doi: 10.1016/S0140-6736(17)30751-1. Epub 2017 Mar 18. PubMed 28325638 ↗
  • Povsic TJ, Roe MT, Ohman EM, Steg PG, James S, Plotnikov A, Mundl H, Welsh R, Bode C, Gibson CM. A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study. Am Heart J. 2016 Apr;174:120-8. doi: 10.1016/j.ahj.2016.01.004. Epub 2016 Jan 18. PubMed 26995378 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2015 to primary completion in Oct 2016, 17 months.

Results were first posted in Nov 2017, 1 year after primary completion.

Of 30 phase 2 interventional studies under Acute Coronary Syndrome, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2014
First posted
Nov 18, 2014
StartActual
Apr 20, 2015
Primary completionActual
Oct 14, 2016
CompletionActual
Oct 14, 2016
Results first posted
Nov 13, 2017
Last update
Dec 26, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 26, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02293395
Collaborators
Bayer, Duke Clinical Research Institute, Harvard Medical School (HMS and HSDM)
Responsible party
Sponsor
First posted
Nov 18, 2014
Start date
Apr 20, 2015
Primary completion
Oct 14, 2016
Completion
Oct 14, 2016
Results posted
Nov 13, 2017
Last update
Dec 26, 2017

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rivaroxaban · Clopidogrel · Ticagrelor

Start the discussion